Compare Merck & Co., Inc. (MRK) vs Progressive Corp (PGR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Progressive Corp — how do they compare? Merck & Co., Inc. trades at $144.97 (market cap $351.28B), while Progressive Corp trades at $218.35 (market cap $126.95B). The key difference: Merck & Co., Inc. is far larger — about 2.8× Progressive Corp's market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Progressive Corp for 81 Days on average.
| MRK | PGR | |
|---|---|---|
Market Cap | $351.28B | $126.95B |
Volume | 7,969,665 | 2,749,438 |
Sector | Health | Financials |
52-Week High | $156.43 | $242.16 |
52-Week Low | $82.49 | $190.40 |
Typical Hold Time | 98 Days | 81 Days |
Enterprise Value | $398.04B | $135.16B |
Dividend Yield | 2.39% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Progressive Corporation (PGR) trades at $214.12, up 0.98% with a bullish technical outlook supported by moving averages. The company demonstrates strong fundamentals with revenue growth from $49.6B in 2022 to $87.6B in 2025 and robust profitability metrics including 34.94% ROE. Recent earnings show mixed results with Q2 2026 beating expectations while Q1 2026 missed. Analyst consensus leans neutral with 52.38% hold ratings but a $222.23 price target suggests modest upside potential from current levels.
PGR presents a balanced investment case with solid fundamentals and reasonable valuation (P/E 10.97) offset by competitive pressures in personal auto insurance. The stock's technical strength and consistent revenue growth support potential upside, though investors should monitor underwriting discipline amid intensifying market competition. Key risks include execution challenges and macroeconomic sensitivity affecting insurance demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →
